Biologics-In-A-Pill Firm PsiThera Launched With Series A $47.5m

 
• By Andrew McConaghie
  
The structure of Tumor Necrosis Factor (TNF) makes it a challenging target for small molecule drugs.

More from R&D

More from Scrip